#China #Suzhou #Biologics Development #Altruist Biologics #Altru-CON™

Altruist Biologics Launches Altru-CON™

In a significant advancement for the biotechnology sector, Altruist Biologics, a subsidiary of Innovent Biologics, has unveiled its cutting-edge Altru-CON™ platform. This innovative system is designed to expedite the development and commercialization of high-dose biologics, addressing the growing demand for efficient drug formulations.

What is Altru-CON™?

The newly introduced Altru-CON™ leverages proprietary excipient blends along with advanced technology to not only enhance drug delivery but also ensure stability for biologics. With the ability to support protein concentrations up to 200 mg/mL, the platform aims to streamline the development processes, promising to cut the Investigational New Drug (IND) timelines to under nine months. Furthermore, it ensures stable formulations can be achieved for subcutaneous administration, a method preferred by patients and healthcare providers alike.

Breaking New Ground in Biologics

As the biologics industry evolves, the push toward higher drug concentrations and more user-friendly delivery methods has become paramount. Altru-CON™ offers dual breakthroughs in both concentration and stability by utilizing a high-throughput screening approach. This optimized system incorporates over 30 excipient combinations to create stable formulations that maintain low viscosity, making them suitable for patient administration.

High-concentration biologics face considerable challenges, including protein interactions, viscosity management, and long-term stability—all of which can complicate manufacturing efforts. Altru-CON™ effectively addresses these concerns, providing greater flexibility in injection volumes, reducing dosing frequencies, and simplifying cold chain logistics. This innovation not only enhances drug substance and product manufacturing efficiency but also significantly improves the likelihood of successful IND submissions.

Enhanced Development Approach

Altruist Biologics takes a structured approach to candidate selection, integrating the high-throughput screening of over 40 buffer systems to assess viscosity and predict aggregation risks. This methodology not only mitigates the risks associated with late-stage reformulations but significantly enhances the probability of approval for new biologics. So far, Altruist has supported one approved high-concentration product and is involved in various stages of other clinical programs.

Dr. Kaisong Zhou, Chairman and CEO of Altruist Biologics, stated, “Altru-CON™ signifies a tactical expansion of our capabilities in high-concentration formulations, aiding the progression of next-generation biologics from low to ultra-high concentrations with superior stability and viscosity control. Our integrated drug formulation expertise, along with a client-centric approach, empowers us to assist partners in advancing therapies for patient benefits.”

With a commitment to fostering innovation and supporting partners in the competitive landscape of biotech, Altruist Biologics is setting the stage for the efficient development of biologics.

About Altruist Biologics

Based in Suzhou, China, Altruist Biologics is dedicated to the development, clinical, and commercial manufacturing of a variety of biopharmaceuticals, including antibodies and fusion proteins. Their state-of-the-art facilities are compliant with Good Manufacturing Practices (GMP) and meet rigorous international regulatory standards, ensuring clients receive high-quality services that enhance patient outcomes worldwide.

For further details regarding Altruist Biologics and its development platforms, visit www.altruistbio.com.